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Background: The DIAD study is a randomized, prospective, multicenter trial examining whether screening asymptomatic diabetics with adenosine-
stress radionuclide myocardial perfusion imaging (MPI) affects their cardiac outcomes. As recently reported, cardiac event rates in the overall cohort 
were relatively low (~0.6%/year) and similar in screened and unscreened subjects. The purpose of this analysis was to determine whether patients 
with metabolic syndrome (MS) represent a significantly higher risk group and whether this subgroup would benefit from MPI screening.
Methods: Patients with type 2 diabetes patients with and without MS were identified in the DIAD trial according to the American Heart Association 
criteria. We analyzed their MPI results and outcomes over an average of 4.8 years of follow-up. The primary outcome was cardiac death (CD) or 
nonfatal myocardial infarction (MI) and secondary outcomes included heart failure, unstable angina and stroke. Comparison was made using log-
rank and chi-square analysis.
Results: Of 1123 patients enrolled in the DIAD trial, 799 (71%) patients had MS with 397 (71%) in the screened group and 402 (70%) in the 
not-screened group. Of 521 participant who completed screening, 364 (69%) had MS. There was no difference in incidence of abnormal MPI and 
moderate/large MPI defects in those with and without MS [abnormal MPI 76 (21%) vs. 37(24%); moderate/large defects 25 (6.8%) vs. 8 (5%)]. 
Overall 32 primary cardiac events occurred: 20 MI (1.8%) and 12 CD (1.1%). Primary cardiac event rate was similar in participants with and without 
MS [overall 27 (3.3%) vs. 5 (1.5%) , MI 17 (2.1%) vs. 3 (0.9%), CD 10 (1.2%) vs. 2 (0.6%)] and in those with and without MS who had screening and 
no-screening. There was also no difference in secondary events in participants with and without MS and with and without screening.
Conclusion: Asymptomatic patients with type 2 diabetes and MS were not a high-risk subgroup in the DIAD trial. The incidence of abnormal MPI 
and primary and secondary cardiac events was similar in DIAD participants with and without MS. Additionally, in this subgroup of DIAD participants 
with MS, screening for myocardial ischemia also had no impact on their cardiac outcomes.
